
|Videos|January 13, 2016
Dr. Adam Kibel on Treating Bone Metastases in Prostate Cancer
Author(s)Adam Kibel, MD
Kibel cited both the STAMPEDE and CHAARTED trials, which showed the efficacy of docetaxel plus androgen deprivation therapy (ADT) in metastatic prostate cancer.
Advertisement
prostate cancer
Adam Kibel, MD, chief of urology, Dana Farber Cancer Institute, Brigham and Women's Hospital, discusses how to properly treatpatients with bone metastases and what the goals of the treatments are.
Kibel cited both the STAMPEDE and CHAARTED trials, which showed the efficacy of docetaxel plus androgen deprivation therapy (ADT) in metastatic prostate cancer. The combination significantly improved overall survival (OS), which Kibel says is proof enough to implement docetaxel in patients with bone metastatic cancer.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































